Global Oncolytic Virus Therapies Market

Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

Published Year:
SKU:BHP1031SA

$5000

Online Access for 1-3 Users. Permission to Print.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Report Description

Market Report Coverage - Oncolytic Virus Therapies
Forecast Period: 2020-2030
Market Size in 2019: $84.3 Million

Market Report Coverage - Oncolytic Virus Therapies

Base Year

2019

Market Size in 2019

$84.3 Million

Forecast Period

2020-2030

Value Projection and Estimation by 2030

$962.0 Million

CAGR During Forecast Period

26.28%

Number of Tables

12

Number of Pages

179

Number of Figures

134

Research Hours

 

 

 

Market Segmentation

•    Commercialized Therapies: Imlygic, Oncorine, and RIGVIR

•    Pipeline Therapies: Phase I, Phase II, Phase III

•    Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)

•    Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)

Regional Segmentation

•    North America: U.S.

•    Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-Europe (Spain, Russia, Switzerland)

•    Asia-Pacific – Japan, China, Rest-of-APAC (India, Australia, South Korea)

Growth Drivers

•    Increasing Incidence of Cancer

•    Rising Number of Clinical Trials

•    Increasing Research Funding from National Cancer Institute

•    Increasing Adoption of Inorganic Growth Strategies in the Market

Market Restraints

•    High Cost of Therapy

•    Lack of Therapy-Specific Assays

Market Opportunities

•    Opportunities in the Emerging Economies

•    Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies

Key Companies Profiled

Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.

Key Questions Answered in this Report:

What is the COVID-19 impact on the global oncolytic virus therapies market?

•       What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?
•       What are the key development strategies being implemented by the major players in order to sustain in the competitive market? 
•       What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?
•       How is each segment of the market expected to grow during the forecast period 2020-2030?
•       Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?
•       What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world? 
•       What is the COVID-19 impact on the global oncolytic virus therapies market?
•       Which companies are anticipated to be highly disruptive in the future, and why?
•       What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?
•       What are the dynamics of various application areas and countries, which are impacting the global oncolytic virus therapies market?
•       What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?
•       How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types: 
        o    Commercialized Therapies 
        o    Pipeline Therapies
        o    Type of Virus
        o    Application
        o    Region

Market Overview

The global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.

Oncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body. These therapies aim at modifying genetic material for the treatment of a disease. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells. Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.

Our healthcare experts have found oncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.

Factors fueling the growth of the market include prevalence of cancer, rising number of clinical trials, boosting research funding, and adoption of inorganic growth. Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth such as the relatively high total costs of therapies and lacking therapy-specific assay. Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.

Within the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the cases of cancer on the global level has created a buzz among companies to invest in the therapeutics of advanced technologies. Due to a large number of pipeline therapies and intense market penetration, oncolytic virus therapies have been pioneers in the therapeutic field and have significant competitors in this market.

Based on region, North America held the largest share in 2020, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

Download this TOC

Request a Sample

1.1    Inclusion and Exclusion

2.1    Scope of Work
2.2    Key Questions Answered in the Report

3.1    Global Oncolytic Virus Therapies Market: Research Methodology
3.2    Primary Data Sources
3.3    Secondary Data Sources
3.4    Market Estimation Model
3.5    Criteria for Company Profiling

4.1    Market Definition
4.2    Importance of Oncolytic Virus Therapies in Cancer Treatment
4.3    Market Size and Growth Potential, $Million, 2019-2030
4.4    COVID-19 Impact on the Global Oncolytic Virus Therapies Market

5.1    Overview
5.2    Regulatory Scenario
5.3    Legal Requirements and Framework in the U.S
         5.3.1    Clinical Trial Authorization
         5.3.2    U.S. FDA Guidelines for BLA Submission
5.4    Legal Requirements and Framework in Europe
         5.4.1    EMA Biologics License Application Process
         5.4.2    Centralized Procedure
         5.4.3    Decentralized Procedure
         5.4.4    Mutual-Recognition Procedure
5.5    Legal Requirements and Framework in Asia-Pacific
         5.5.1    China
         5.5.2    Japan
5.6    Expedited Regulatory Designations Around the World
5.7    Reimbursement Scenario
5.8    Patent Analysis
         5.8.1    Patent Filing Trend

6.1    Overview
6.2    Impact Analysis
6.3    Market Drivers
         6.3.1    Increasing Incidence of Cancer
         6.3.2    Rising Number of Clinical Trials
         6.3.3    Increasing Research Funding from National Cancer Institute
         6.3.4    Increasing Adoption of Inorganic Growth Strategies in the Market
6.4    Market Restrains
         6.4.1    High Cost of Therapy
         6.4.2    Lack of Therapy-Specific Assays
6.5    Market Opportunities
         6.5.1    Opportunities in the Emerging Economies
         6.5.2    Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies

7.1    Synergistic Activities
7.2    Business Expansion Activities and Others
7.3    Product Launches and Product Updates
7.4    Mergers and Acquisitions
7.5    Market Share Analysis
7.6    Growth Share Analysis
         7.6.1    Growth Share Analysis (by Commercialized Therapy)

Oncolytic Virus Therapies: Epidemiology Analysis

9.1    Overview
9.2    Imlygic
9.3    Oncorine
9.4    RIGVIR

10.1    Overview
10.2    Phase I
10.3    Phase II
10.4    Phase III
10.5    Phase IV

11.1    Overview
11.2    Genetically Engineered Oncolytic Virus
           11.2.1    Herpes Simplex Virus (HSV)
           11.2.2    Adenovirus
           11.2.3    Vaccinia Virus
11.3    Oncolytic Wild-Type Virus
           11.3.1    Reovirus (Respiratory Enteric Orphan Virus)
           11.3.2    Newcastle Disease Virus (NDV)
           11.3.3    Vesicular Stomatitis Virus (VSV)

12.1    Overview
12.2    Solid Tumor
           12.2.1    Breast Cancer
           12.2.2    Prostate Cancer
           12.2.3    Lung Cancer
           12.2.4    Glioblastoma
           12.2.5    Melanoma
           12.2.6    Other Applications
12.3    Hematological Malignancies
           12.3.1    Lymphoma
           12.3.2    Leukemia
           12.3.3    Myeloma

13.1    Overview
13.2    North America
           13.2.1    U.S.
13.3    Europe
           13.3.1    U.K.
           13.3.2    Latvia
           13.3.3    Georgia
           13.3.4    Armenia
           13.3.5    Germany
           13.3.6    France
           13.3.7    Italy
           13.3.8    Rest-of-Europe
13.4    Asia-Pacific
           13.4.1    China
           13.4.2    Japan
           13.4.3    Rest-of-APAC

14.1    Overview
14.2    Amgen Inc.
           14.2.1    Company Overview
           14.2.2    Role of Amgen Inc. in the Global Oncolytic Virus Therapies Market
           14.2.3    Financials
           14.2.4    Key Insights about Financial Health of the Company
           14.2.5    SWOT Analysis
14.3    DAIICHI SANKYO COMPANY, LIMITED
           14.3.1    Company Overview
           14.3.2    Role of DAIICHI SANKYO COMPANY, LIMITED in the Global Oncolytic Virus Therapies Market
           14.3.3    Financials
           14.3.4    Key Insights About Financial Health of the Company
           14.3.5    SWOT Analysis
14.4    DNAtrix
           14.4.1    Company Overview
           14.4.2    Role of DNAtrix in the Global Oncolytic Virus Therapies Market
           14.4.3    SWOT Analysis
14.5    Genelux
           14.5.1    Company Overview
           14.5.2    Role of Genelux in the Global Oncolytic Virus Therapies Market
           14.5.3    SWOT Analysis
14.6    Oncolytics Biotech, Inc.
           14.6.1    Company Overview
           14.6.2    Role of Oncolytics Biotech, Inc. in the Global Oncolytic Virus Therapies Market
           14.6.3    Financials
           14.6.4    SWOT Analysis
14.7    PsiOxus Therapeutics
           14.7.1    Company Overview
           14.7.2    Role of PsiOxus Therapeutics in the Global Oncolytic Virus Therapies Market
           14.7.3    SWOT Analysis
14.8    RIGVIR Ltd.
           14.8.1    Company Overview
           14.8.2    Role of RIGVIR Ltd. in the Global Oncolytic Virus Therapies Market
           14.8.3    SWOT Analysis
14.9    Shanghai Sunway Biotech Co., Ltd.,
           14.9.1    Company Overview
           14.9.2    Role of Shanghai Sunway Biotech Co., Ltd., in the Global Oncolytic Virus Therapies Market
           14.9.3    SWOT Analysis
14.10    SillaJen, Inc.
             14.10.1    Company Overview
             14.10.2    Role of SillaJen, Inc. in the Global Oncolytic Virus Therapies Market
             14.10.3    SWOT Analysis
14.11    Sorrento Therapeutics, Inc.
             14.11.1    Company Overview
             14.11.2    Role of Sorrento Therapeutics, Inc. in Global Oncolytic Virus Therapies Market
             14.11.3    Financials
             14.11.4    Key Insights About Financial Health of the Company
             14.11.5    SWOT Analysis
14.12    Takara Bio Inc.
             14.12.1    Company Overview
             14.12.2    Role of Takara Bio Inc. in the Global Oncolytic Virus Therapies Market
             14.12.3    Financials
             14.12.4    Key Insights About Financial Health of the Company
             14.12.5    SWOT Analysis
14.13    Transgene sa
             14.13.1    Company Overview
             14.13.2    Role of Transgene sa in the Global Oncolytic Virus Therapies Market
             14.13.3    Financials
             14.13.4    SWOT Analysis
14.14    VCNBiosciences
             14.14.1    Company Overview
             14.14.2    Role of VCNBiosciences in the Global Oncolytic Virus Therapies Market
             14.14.3    SWOT Analysis
14.15    ViroCure
             14.15.1    Company Overview
             14.15.2    Role of ViroCure in the Global Oncolytic Virus Therapies Market
             14.15.3    SWOT Analysis
14.16    Viralytics Ltd. (Merck & Co., Inc.)
             14.16.1    Company Overview
             14.16.2    Role of Merck & Co., Inc. in the Global Oncolytic Virus Therapies Market
             14.16.3    Financials
             14.16.4    Key Insights About Financial Health of the Company
             14.16.5    SWOT Analysis

Table 5.1:    Regulatory Scenario Across the World
Table 5.2:    Expedited Regulatory Designations Around the World
Table 5.3:    Key Market Access Landscape (by Country), January 2019
Table 9.1:    Commercialized Therapies
Table 10.1:    Key Oncolytic Virus Therapies in Clinical Development Phase I, 2020
Table 10.2:    Key Oncolytic Virus Therapies in Clinical Development Phase II, 2020
Table 10.3:    Key Oncolytic Virus Therapies in Clinical Development Phase III, 2020
Table 11.1:    Key Herpes Simplex Virus (HSV)-Based Oncolytic Therapies
Table 11.2:    Key Adenovirus-Based Oncolytic Therapies
Table 11.3:    Key Vaccinia Virus-Based Oncolytic Therapies
Table 11.4:    Key Reovirus-Based Oncolytic Therapies
Table 13.1:    Rest-of-APAC - Pipeline Drugs

Figure 1:    NCI Fiscal Budget Year on Year, 2013-2018
Figure 2:    Impact Analysis of Market Drivers and Market Challenges on the Global Oncolytic Virus Therapies Market
Figure 3:    Global Oncolytic Virus Therapies Market (by Application), $Million,  2019 Vs. 2030
Figure 4:    Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019 vs. 2030
Figure 5:    Global Oncolytic Virus Therapies Market Snapshot, $Million, 2019 and 2030
Figure 2.1:    Global Oncolytic Virus Therapies Market Segmentation
Figure 3.1:    Global Oncolytic Virus Therapies Market Research Methodology
Figure 3.2:    Primary Research Methodology
Figure 3.3:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4:    Top-Down Approach (Segment-Wise Analysis)
Figure 4.1:    Global Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 4.2:    Global Oncolytic Virus Therapies Market: COVID-19 Impact
Figure 5.1:    Clinical Trial Authorization for Oncolytic Virus Therapies
Figure 5.2:    Steps for Obtaining Marketing Authorization
Figure 5.3:    U.S. FDA Expedited Review Programs
Figure 5.4:    Regulatory Strategy for Oncolytic Virus Therapies in the U.S.
Figure 5.5:    U.S.FDA Review Timeline
Figure 5.6:    Regulatory Strategy for Oncolytic Virus Therapies in Europe
Figure 5.7:    EMA Review Timeline
Figure 5.9:    Overview of PMDA and MLHW Drug Approval Process in Japan
Figure 5.10:    Global Oncolytic Virus Therapies Market: Patent Analysis (by Country and Year), January 2015-March 2021
Figure 6.1:    Impact Analysis
Figure 6.2:    Cancer Cases Projection, 2016-2020
Figure 6.3:    Number of Active and Completed Clinical Trials for Gene Therapy (by Start Date), 2015-2019
Figure 6.4:    SBIR and STTR Grants and Contract Funding, 2008-2018
Figure 6.5:    NCI Fiscal Budget Year-on-Year, 2013-2018
Figure 6.6:    Synergistic Activities, 2018-2020
Figure 7.1:    Share of Key Developments and Strategies, January 2018-March 2021
Figure 7.2:    Synergistic Activities Share (by Company), January 2018-March 2021
Figure 7.3:    Business Expansion Activities Share (by Company), January 2018-March 2021
Figure 7.4:    Number of Product Launches (by Company), January 2018-March 2021
Figure 7.5:    Mergers and Acquisitions, January 2018-March 2021
Figure 7.6:    Market Share Analysis for Global Oncolytic Virus Therapies Market, (by Application), $Million, 2020
Figure 7.7:    Growth Share Analysis for Global Oncolytic Virus Therapies Market (by Commercialized Therapy), 2019-2020
Figure 8.1:    Type of Cancer
Figure 8.2:    Global Estimated Percent of New Cancer Cases (by Sex), 2030
Figure 8.3:    Expected Cancer Cases in the World (by Country), 2030
Figure 8.4:    Relative Number of Expected New Cancer Cases (by Country), 2030
Figure 9.1:    Global Oncolytic Virus Therapies Market (Imlygic), $Million, 2019-2030
Figure 9.2:    Global Oncolytic Virus Therapies Market (Oncorine), $Million, 2019-2030
Figure 9.3:    Global Oncolytic Virus Therapies Market (RIGVIR), $Million, 2019-2030
Figure 10.1:    Oncolytic Virus Gene Therapy Medicines in Development (by Disease), 2019
Figure 11.1:    Global Oncolytic Virus Therapies Market (by Type of Virus), $Million,  2019-2030
Figure 11.2:    Global Oncolytic Virus Therapies Market (by Genetically Engineered Oncolytic Virus), $Million, 2019 and 2030
Figure 11.3:    Global Oncolytic Virus Therapies Market (Herpes Simplex Virus), $Million, 2019-2030
Figure 11.4:    Global Oncolytic Virus Therapies Market (Adenovirus), $Million, 2019-2030
Figure 11.5:    Global Oncolytic Virus Therapies Market (Vaccinia Virus), $Million, 2019-2030
Figure 11.6:    Global Oncolytic Virus Therapies Market (by Oncolytic Wild-Type Virus), $Million, 2019 and 2030
Figure 11.7:    Global Oncolytic Virus Therapies Market (Reovirus), $Million, 2019-2030
Figure 11.8:    Global Oncolytic Virus Therapies Market (Newcastle Disease Virus), $Million, 2019-2030
Figure 11.9:    Global Oncolytic Virus Therapies Market (Vesicular Stomatitis Virus), $Million, 2019-2030
Figure 12.1:    Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-2030
Figure 12.2:    Global Oncolytic Virus Therapies Market (by Solid Tumor), $Million,  2019 and 2030
Figure 12.3:    Global Oncolytic Virus Therapies Market (Breast Cancer), $Million, 2019-2030
Figure 12.4:    Global Oncolytic Virus Therapies Market (Prostate Cancer), $Million,  2019-2030
Figure 12.5:    Global Oncolytic Virus Therapies Market (Lung Cancer), $Million, 2019-2030
Figure 12.6:    Global Oncolytic Virus Therapies Market (Glioblastoma), $Million, 2019-2030
Figure 12.7:    Global Oncolytic Virus Therapies Market (Melanoma), $Million, 2019-2030
Figure 12.8:    Global Oncolytic Virus Therapies Market (Other Applications), $Million, 2019-2030
Figure 12.9:    Global Oncolytic Virus Therapies Market (by Haematological Malignancies), $Million, 2019 and 2030
Figure 12.10:    Global Oncolytic Virus Therapies Market (Lymphoma), $Million, 2019-2030
Figure 12.11:    Global Oncolytic Virus Therapies Market (Leukemia), $Million, 2019-2030
Figure 12.12:    Global Oncolytic Virus Therapies Market (Myeloma), $Million, 2019-2030
Figure 13.1:    Global Oncolytic Virus Therapies Market (by Region), 2019-2030
Figure 13.2:    Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-2030
Figure 13.3:    Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2019
Figure 13.4:    Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2030
Figure 13.5:    North America Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.6:    North America: Market Dynamics
Figure 13.7:    U.S. Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.8:    Europe Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.9:    Europe: Market Dynamics
Figure 13.10:    Europe Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030
Figure 13.11:    U.K. Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.12:    Latvia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.13:    Georgia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.14:    Armenia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.15:    Germany Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.16:    France Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.17:    Italy Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.18:    Rest-of-Europe Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.19:    Asia-Pacific Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.20:    APAC: Market Dynamics
Figure 13.21:    APAC Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030
Figure 13.22:    China Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.23:    Japan Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.24:    RoAPAC Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 14.1:    Total Number of Companies Profiled
Figure 14.2:    Amgen Inc.: Product Portfolio
Figure 14.3:    Amgen Inc.: Overall Financials, $Million, 2018-2020
Figure 14.4:    Amgen Inc.: Revenue (by Region), $Million, 2018-2020
Figure 14.5:    Amgen Inc. R&D Expenditure, $Billion, 2018-2020
Figure 14.6:    Amgen Inc.: SWOT Analysis
Figure 14.7:    DAIICHI SANKYO COMPANY, LIMITED: Product Portfolio
Figure 14.8:    DAIICHI SANKYO COMPANY, LIMITED: Overall Financials, $Billion, 2017-2019
Figure 14.9:    Amgen Inc. R&D Expenditure, $Billion, 2017-2019
Figure 14.10:    DAIICHI SANKYO COMPANY, LIMITED: SWOT Analysis
Figure 14.11:    DNAtrix: Product Portfolio
Figure 14.12:    DNAtrix: SWOT Analysis
Figure 14.13:    Genelux: Product Portfolio
Figure 14.14:    Genelux: SWOT Analysis
Figure 14.15:    Oncolytics Biotech, Inc.: Product Portfolio
Figure 14.16:    Oncolytics Biotech, Inc.: SWOT Analysis
Figure 14.17:    PsiOxus Therapeutics: Pipeline Product Portfolio
Figure 14.18:    PsiOxus Therapeutics: SWOT Analysis
Figure 14.19:    RIGVIR Ltd.: Overall Service Portfolio
Figure 14.20:    RIGVIR Ltd.: SWOT Analysis
Figure 14.21:    Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
Figure 14.22:    Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
Figure 14.23:    SillaJen, Inc.: Product Portfolio
Figure 14.24:    SillaJen, Inc.: SWOT Analysis
Figure 14.25:    Sorrento Therapeutics, Inc.: Product Portfolio
Figure 14.26:    Sorrento Therapeutics, Inc.: Overall Financials, 2017-2019
Figure 14.27:    Sorrento Therapeutics, Inc. R&D Expenditure, $Million, 2017-2019
Figure 14.28:    Sorrento Therapeutics, Inc.: SWOT Analysis
Figure 14.29:    Takara Bio Inc.: Product Portfolio
Figure 14.30:    Takara Bio Inc.: Overall Financials, 2017-2019
Figure 14.31:    Takara Bio Inc.: Revenue (by Segment), $Million, 2017-2019
Figure 14.32:    Takara Bio Inc.: Revenue (by Region), $Million, 2017-2019
Figure 14.33:    Takara Bio Inc.: R&D Expenditure, 2017-2019
Figure 14.34:    Takara Bio Inc.: SWOT Analysis
Figure 14.35:    Transgene sa: Product Portfolio
Figure 14.36:    Transgene sa: Overall Financials, $Million, 2017-2019
Figure 14.37:    Transgene sa: SWOT Analysis
Figure 14.38:    VCNBiosciences: Pipeline Product Portfolio
Figure 14.39:    VCNBiosciences: SWOT Analysis
Figure 14.40:    ViroCure: Product Portfolio
Figure 14.41:    ViroCure: SWOT Analysis
Figure 14.42:    Viralytics Ltd., (Merck & Co., Inc.): Product Portfolio
Figure 14.43:    Merck & Co., Inc.: Overall Financials, $Million, 2018-2020
Figure 14.44:    Merck & Co., Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 14.45:    Merck & Co., Inc.: Revenue (by Region), $Million, 2018-2020
Figure 14.46:    Merck & Co., Inc.: R&D Expenditure, $Million, 2018-2020
Figure 14.47:    Merck & Co., Inc.: SWOT Analysis

Report Description

Market Report Coverage - Oncolytic Virus Therapies

Base Year

2019

Market Size in 2019

$84.3 Million

Forecast Period

2020-2030

Value Projection and Estimation by 2030

$962.0 Million

CAGR During Forecast Period

26.28%

Number of Tables

12

Number of Pages

179

Number of Figures

134

Research Hours

 

 

 

Market Segmentation

•    Commercialized Therapies: Imlygic, Oncorine, and RIGVIR

•    Pipeline Therapies: Phase I, Phase II, Phase III

•    Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)

•    Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)

Regional Segmentation

•    North America: U.S.

•    Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-Europe (Spain, Russia, Switzerland)

•    Asia-Pacific – Japan, China, Rest-of-APAC (India, Australia, South Korea)

Growth Drivers

•    Increasing Incidence of Cancer

•    Rising Number of Clinical Trials

•    Increasing Research Funding from National Cancer Institute

•    Increasing Adoption of Inorganic Growth Strategies in the Market

Market Restraints

•    High Cost of Therapy

•    Lack of Therapy-Specific Assays

Market Opportunities

•    Opportunities in the Emerging Economies

•    Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies

Key Companies Profiled

Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.

Key Questions Answered in this Report:

•       What are the major market drivers, challenges, and opportunities in the global oncolytic virus therapies market?
•       What are the key development strategies being implemented by the major players in order to sustain in the competitive market? 
•       What are the key regulatory implications in developed and developing regions for the global oncolytic virus therapies market?
•       How is each segment of the market expected to grow during the forecast period 2020-2030?
•       Who are the leading players with significant offerings to the global oncolytic virus therapies market, and what is the expected market dominance for each of these leading players?
•       What are the adoption trends for oncolytic virus therapies in established economies and emerging economies across the world? 
•       What is the COVID-19 impact on the global oncolytic virus therapies market?
•       Which companies are anticipated to be highly disruptive in the future, and why?
•       What are the unmet needs that are yet to be met by the global oncolytic virus therapies with respect to the application areas?
•       What are the dynamics of various application areas and countries, which are impacting the global oncolytic virus therapies market?
•       What are the new market opportunities of various technologies that are influencing the growth of the global oncolytic virus therapies market?
•       How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segment types: 
        o    Commercialized Therapies 
        o    Pipeline Therapies
        o    Type of Virus
        o    Application
        o    Region

Market Overview

Oncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body. These therapies aim at modifying genetic material for the treatment of a disease. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells. Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.

Our healthcare experts have found oncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.

Factors fueling the growth of the market include prevalence of cancer, rising number of clinical trials, boosting research funding, and adoption of inorganic growth. Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth such as the relatively high total costs of therapies and lacking therapy-specific assay. Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.

Within the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the cases of cancer on the global level has created a buzz among companies to invest in the therapeutics of advanced technologies. Due to a large number of pipeline therapies and intense market penetration, oncolytic virus therapies have been pioneers in the therapeutic field and have significant competitors in this market.

Based on region, North America held the largest share in 2020, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.

FAQ's

What is the growth rate of global oncolytic virus therapies market in the coming decade?

The global oncolytic virus therapies market is projected to grow at a whopping CAGR of 26.28% over the period 2020-2030 and reach a market value of $962 million by 2030. 

What are the business drivers that push the demand for oncolytic virus therapies?

Several factors such as the increasing incidence of cancer, rising number of clinical trials, increasing research funding from National Cancer Institute, and increasing adoption of inorganic growth strategies in the market, favour the growth of this emerging tech. 

Are there any challenges associated with the global oncolytic virus therapies market?

High cost of therapy and lack of therapy-specific-assays may cause hindrance in the adoption of oncolytic virus therapies globally. 

Which region occupied the highest market share in the oncolytic virus therapies industry?

In 2020, the North American region held the largest share in the global market for oncolytic virus therapies owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. 

Who are the key companies operating in the oncolytic virus therapies market?

The major market share holders in the oncolytic virus therapies industry include DNAtrix, Daiichi Sankyo Company Ltd., Takara Bio Inc., Sorrento Therapeutics Inc., ViroCure, Shanghai Sunway Biotech Co. Ltd., and VCN Biosciences, among others. 

You may also like

Published Year:2020

Global PD-1/PD-L1 Immunotherapy Market: Focus on Type, Application, Country Data (14 Countries), and

The global market for PD-1/PD-L1 immunotherapy is predicted to grow at a CAGR of 10.72% over...

Published Year:2019

Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Compet

The global cancer immunotherapy market was valued at $39.86 billion in 2017 and is anticipated...

Global Oncolytic Virus Therapies Market

Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030